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Abstract 
 
Molecular Targets of Psychedelics and Their Role in Behavioral Models of Hallucinogenic 
Action 
 
By Hiba Zainab Vohra 
 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science in Physiology and Biophysics at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2019 
 
Director: Javier González-Maeso 
Associate Professor 
Department of Physiology and Biophysics 
 
 Psychedelics are a subset of hallucinogenic drugs that exert their characteristic effects 
through agonist activity at the serotonin receptor 2A (5-HT2A). In this study, I aimed to 
characterize the modulatory role of the metabotropic glutamate subtype 2 receptor (mGluR2) in 
the 5-HT2A-specific rodent model of hallucinogenic action, head-twitch response (HTR). 
Secondly, I aimed to explore if 5-HT2A agonist-induced deficits in prepulse inhibition (PPI) of 
the startle response, an additional model of hallucinogenic action, could be produced in mice. 
Though 5-HT2A agonist-induced PPI deficits, which represent interruptions in normal 
sensorimotor gating, have been described in both rats and humans, attempts to translate this 
behavior to mice are rare. In contrast to prior gene knockout studies suggesting the mGluR2 is 
necessary for 5-HT2A agonist-induced HTR, mGluR2 knockout (Grm2-/-) mice still displayed 
HTR upon administration of the psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI). 
Additionally, DOI and lysergic acid diethylamide (LSD) produced unexpected improvements in 
PPI in male 126S6/Sv wild-type mice, depending on the experimental protocol used and the 
origin of the animals. Sex differences were observed as DOI-induced improvements in PPI were 
present in female 129S6/Sv mice of the same origin and tested with the same protocol as their 
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male counterparts; this effect in females was absent in 5-HT2A knockout (Htr2a-/-) mice. The 
results of this study shed light on issues with replicability and reproducibility in science, the 
importance of highlighting the origin and background of animal subjects, and potential sex 
differences in hallucinogenic drug action. 
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Chapter 1: Introduction 
 
Psychedelics 
 
Psychedelics are psychoactive substances that alter perception, emotion, and cognition, 
exerting their effects through the serotonin receptor 2A (5-HT2A). They are also known as classic 
serotonergic hallucinogens, a subset of hallucinogenic drugs that share a common mechanism of 
action in producing altered states of consciousness (Nichols, 2016). Psychedelics can be divided 
into three categories based on their structural and behavioral characteristics: ergolines, 
tryptamines, and phenethylamines (Winter, 2009). Lysergic acid diethylamide (LSD) is 
categorized as an ergoline (Nichols, 2004); however, it is important to note that its chemical 
structure contains components of both tryptamines and phenethylamines (Winter, 2009). 
Tryptamines include N,N-dimethyltryptamine (DMT), 5-methoxy-N,N-dimethyltryptamine 
(MDMT), psilocybin, and its derivative psilocin; phenethylamines include mescaline, 2,5-
dimethoxy-4-methylamphetamine (DOM), and 2,5-dimethoxy-4-iodoamphetamine (DOI) 
(Shulgin & Shulgin, 1990; Winter, 2009). 
Naturally sourced psychedelic compounds from plants and mushrooms have been 
consumed by humans for centuries for spiritual and religious purposes (Nichols, 2004), but the 
introduction of psychedelics to the modern era began with the accidental discovery of LSD’s 
mind-altering effects by chemist Albert Hoffman in 1943. Below is his description of his 
experience: 
Last Friday, April 16, 1943, I was forced to interrupt my work in the laboratory in the 
middle of the afternoon and proceed home, being affected by a remarkable restlessness, 
combined with a slight dizziness. At home I lay down and sank into a not unpleasant 
intoxicated-like condition, characterized by an extremely stimulated imagination. In a 
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dreamlike state, with eyes closed (I found the daylight to be unpleasantly glaring), I 
perceived an uninterrupted stream of fantastic pictures, extraordinary shapes with intense, 
kaleidoscopic play of colors. After some two hours this condition faded away. (Hofmann, 
1980, p. 12).  
This discovery was followed by years of research into the use of LSD and other psychedelic 
substances as tools for psychiatric investigation and as potential treatments for mental illnesses 
(Belouin & Henningfield, 2018). 
 
Figure 1: Comparison of the chemical structures of serotonin and LSD. (A) 5-
hydroxytryptamine (serotonin) and (B) lysergic acid diethylamide (LSD) both contain 
tryptamine, suggesting LSD functions in the brain by interfering with the actions of serotonin. 
ChemDraw Professional 16.0. 
 
 
 
Serotonin hypothesis of hallucinogenic action 
A decade after Hoffman’s discovery, serotonin (5-HT) activity was detected in rat and 
dog brains (Twarog & Page, 1953). Later that year, Gaddum (as cited in Nichols, 2016) found 
that LSD antagonized the effects of 5-HT in peripheral tissues. More specifically, it was 
3 
 
observed the following year that LSD abolished the vasoconstrictor effect of 5-HT in a rabbit ear 
and resulted in a small decrease of the effect of 5-HT on a rat uterus (Gaddum & Hameed, 1954). 
These pieces of evidence, along with the structural similarities between 5-HT and LSD observed 
(Figure 1), led to the hypothesis that LSD specifically functions to produce altered mental states 
by blocking 5-HT in the brain (Gaddum & Hameed, 1954; Woolley & Shaw, 1954). Woolley 
and Shaw expanded the hypothesis to suggest that if LSD induces altered states of 
consciousnesses and does so through interactions with serotonin, then perhaps serotonin plays a 
role in maintaining normal mental processes (1954). 
However, two years later, LSD was shown to mimic the function of 5-HT on the heart of 
clam by producing a stimulatory response, suggesting it was a 5-HT receptor agonist (Shaw & 
Woolley, 1956). Eventually, it was concluded LSD primarily has an agonist effect on 5-HT 
(Aghajanian & Marek, 1999), particularly after additional evidence showed that LSD and 5-
hydroxytryptophan (5-HTP), a precursor to 5-HT, produced similar functional effects on rat 
spinal reflexes (Andén et al., 1968). These findings led to the conclusion that stimulation of a 5-
HT receptor may be responsible for the hallucinogenic effects of LSD (Andén et al., 1968). 
Later, this hypothesis was expanded to include that hallucinogens such as psilocin and mescaline 
also act similarly to LSD at the 5-HT receptor (Aghajanian & Marek, 1999). 
 
5-HT2A receptor as primary target of psychedelics 
From early research in the 1980s and 1990s, seven distinct families of 5-HT receptors 
have been discovered comprising of 14 receptor subtypes in mammalian cells. Most of these 
receptor subtypes are G protein-coupled receptors (GPCRs), though one, the 5-HT3 receptor, is a 
known ligand-gated ion channel (Barnes & Sharp, 1999). GPCRs are a family of receptors 
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characterized by a common motif of seven transmembrane alpha-helices comprising of 
hydrophobic amino acids and an association with intracellular heterotrimeric GTP-binding 
proteins, or G proteins. They can be divided into three classes: A, B, and C, which correspond to 
rhodopsin, secretin, and metabotropic glutamate receptor families, respectively. Upon binding of 
the appropriate ligand, intracellular signaling is mediated through the activation of G proteins 
made up of α, β and γ subunits. The type of G protein associated with the receptor determines its 
intracellular signaling cascade: Gs proteins are stimulatory, Gi/o proteins are inhibitory, and Gq/11 
proteins are also stimulatory and are known to cause downstream effects that lead to increased 
intracellular calcium concentration (Alexander et al., 2011).  
Of the 5-HT receptors, the 5-HT2 receptor family was more specifically implicated in 
mediating the hallucinogenic effects of psychedelics following several drug discrimination 
studies involving the use of 5-HT2 receptor antagonists. In one study, pretreatment of rats with 
the 5-HT2 antagonists ketanserin and pirenperone blocked the discriminative cue of the 
psychedelic DOM and also blocked DOM-stimulus generalization to mescaline and LSD 
(Glennon et al., 1983). Another study also showed a strong correlation between the binding of 
several psychedelics to 5-HT2 in rat cortical tissue preparations and their human hallucinogenic 
potencies (Glennon et al., 1984). Later, the attention shifted to the 5-HT2A receptor subtype as 
the necessary or central target for mediating the hallucinogenic drug effects after studies showed 
that antagonists blocking the action of psychedelics had a higher affinity for the 5-HT2A receptor 
compared to the 5-HT2C receptor (Fiorella et al., 1995).  
 The role of the 5-HT2A receptor was also confirmed through behavioral studies in animals 
and humans. Head-twitch response (HTR), as will be described in a later section, is a behavior 
displayed by rodents upon administration of 5-HT agonists. Willins and Meltzer showed that 
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head-twitch response induced by direct injection of DOI into the medial prefrontal cortex of rats 
was inhibited by pretreatment with the 5-HT2A antagonists ketanserin and M100,907, but not a 
selective 5-HT2C/2B antagonist (1997). This narrowed the essential receptor for mediating HTR to 
the 5-HT2A. Additionally, DOI- and LSD-induced head-twitch response was blocked in 5-HT2A 
knockout mice compared to wild-types, further supporting the role of this receptor in the action 
of psychedelics by using genetically modified animal models (González-Maeso et al., 2003). The 
first evidence in humans of the role of the 5-HT2A receptor in mediating hallucinations was from 
a 1998 study showing that psilocybin-induced psychosis in human subjects was blocked by 
ketanserin and the atypical antipsychotic risperidone, another 5-HT2A antagonist (F. 
Vollenweider et al., 1998).  
The 5-HT2A receptor is a class A GPCR that couples to the Gq/11 protein intracellularly. 
Though psychedelic drugs function through this receptor, not all 5-HT2A agonists produce 
hallucinogenic effects. One study set out to distinguish the responses of hallucinogenic and non-
hallucinogenic 5-HT2A agonists in mouse somatosensory cortex to understand how the receptor 
specifically elicits this unique behavioral effect. Transcriptional responses to DOI, LSD, and the 
non-hallucinogenic 5-HT2A agonist lisuride hydrogen maleate showed increased expression of 
the gene c-fos, whereas only DOI and LSD modulated the expression of the gene egr-2. These 
changes were also absent in 5-HT2A knockout animals, confirming these effects were dependent 
on activation of this receptor (González-Maeso et al., 2003). 
 
 
mGluR2 modulation of hallucinogenic action 
 
The glutamate neurotransmitter system has been shown to play a role in 5-HT2A-mediated 
hallucinogenic drug action, particularly through interaction with the class C Gi/o-coupled 
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metabotropic glutamate receptor subtype 2 (mGluR2). The characteristic induction of c-fos by 5-
HT2A agonists described previously was later shown to be a Gq/11-dependent mechanism, 
whereas LSD- and DOI-induced expression of egr-2 was a Gi/o-dependent mechanism 
(González-Maeso et al., 2008). This hallucinogen-specific expression of egr-2 was blocked by 
treatment with the metabotropic glutamate receptor 2/3 (mGluR2/3) agonist LY379268 in 
primary cortical cultures and in mouse cortex in vivo, whereas the induction of c-fos remained 
unaffected (González-Maeso et al., 2008). Additionally, DOI-induced expression of egr-2 was 
lacking in mGluR2 knockout mice compared to wild-types, further supporting the involvement 
and necessity of the mGluR2 receptor for this pattern of hallucinogen-specific signaling (Moreno 
et al., 2011).  
Though the mechanism through which mGluR2 modulates 5-HT2A-specific behaviors is 
uncertain, there are several theories including interactions through synaptic mechanisms and 
functional crosstalk through a GPCR heterodimer. Marek et al. found through 
electrophysiological studies that activation of presynaptic glutamate receptors by mGluR2 
agonists negatively modulated 5-HT2A receptor-dependent glutamate release in the prefrontal 
cortex (2000). On the other hand, González-Maeso et al. proposed that the 5-HT2A receptor and 
mGluR2 form a heterodimer through which hallucinogens function (2008). Regardless of the 
specific mechanism underlying this interaction, animal behavioral models of hallucinogenic 
action using pharmacological and genetic tools support the involvement of the mGluR2 in some 
capacity. 
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Behavioral models of hallucinogenic action 
 
Two behavioral models of hallucinogenic drug action were the focus of this study: head-
twitch response and prepulse inhibition of the startle reflex. 
 
 
Head-twitch response  
 
Head-twitch response (HTR) is a rhythmic, quick, rotational head movement observed in 
rodents in response to hallucinogenic 5-HT2A agonist administration, as mentioned previously 
(Canal & Morgan, 2012). Though other receptor and neurotransmitter systems have been shown 
to modulate HTR, this behavior is linked specifically to the 5-HT2A receptor (Halberstadt & 
Geyer, 2013b). Typically, head-twitch responses are measured by a trained observer watching 
video recordings of mice behavior. However, this method has the potential to produce 
inconsistent results due to observer biases. Recently, a magnetometer detection system was 
developed by Halberstadt and Geyer to make data collection more standardized (2013a). In this 
procedure, mice are surgically implanted with a small magnet on their scalp. After recovery, they 
are placed in a glass beaker surrounded by magnet wire. When amplification and Fourier 
analysis of the coil output was completed, and head-twitch responses were manually counted by 
identifying sinusoidal wavelets meeting certain criteria characteristic of the rapid side-to-side 
rotational head movement. 
The involvement of the mGluR2 in this 5-HT2A receptor-mediated behavior in rodents 
has been studied by using pharmacological tools in HTR. In Albino-Swiss mice, mGluR2/3 
agonists LY379268 and LY354740 significantly decreased DOI-induced (2.5 mg/kg) HTR in a 
dose-dependent manner (Kłodzinska et al., 2002). A recent study by Halberstadt et al. using male 
C57BL/6J mice also showed that acute pretreatment with LY379268 (10 mg/kg), an mGluR2/3 
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agonist, significantly attenuated head-twitch induced by the 5-HT2A-selective agonist 25CN-
NBOH (1 mg/kg) (2019). On the other hand, administration of an mGluR2/3 antagonist, 
LY341495 (1 mg/kg), enhanced HTR in Sprague-Dawley rats (Gewirtz & Marek, 2000).  
The interaction between these two receptors in HTR has also been modulated through 
chronic administration of 5-HT2A and mGluR2 ligands as a means of inducing receptor 
downregulation or desensitization. In the same aforementioned study by Halberstadt et al., 
administration of the mGluR2/3 agonist LY379268 over a period of 21 days reduced 25CN-
NBOH-induced head-twitch response compared to chronic vehicle-treated mice by roughly 50% 
(2019). Additionally, chronic treatment with the mGluR2/3 antagonist LY341495 decreased 
HTR in 129S6/Sv mice treated with LSD (Moreno et al., 2013). This result is in contrast to the 
enhanced HTR with acute treatment with the same mGluR2/3 antagonist observed by Gewirtz 
and Marek (2013). These differences can be explained by findings from Moreno et al. where 
reduced 5-HT2A receptor binding was observed following chronic treatment with the mGluR2/3 
antagonist LY341495 (2013).  
Additionally, mGluR2 knockout mice have been used as experimental tools to further 
understand the role of this receptor in 5-HT2A-mediated HTR. Moreno et al. showed that while 
DOI and LSD produced significant HTR in wild-type 129S6/Sv mice, no significant HTR was 
observed in mGluR2 knockout mice (2011). Another study by Benvenga et al. replicated these 
results, where DOI produced less head twitch responses in mGluR2 knockout mice compared to 
age-matched wild-type mice and mGluR3 knockout mice (2018). Furthermore, DOI-induced 
head twitches produced by both wild-type and mGluR3 knockout mice were blocked by 
administration of the mGluR2/3 agonist LY379268 and the mGluR2 positive allosteric 
modulator CBiPES (Benvenga et al., 2018). These results suggest the mGluR2 is specifically 
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involved in modulating head-twitch response in comparison with the closely associated mGluR3 
receptor. Moreno et al. also confirmed that the expression of 5-HT2A in the mGluR2 knockout 
mice used in their study was not significantly changed from wild-type mice, further supporting 
the role of mGluR2 in this behavior (2011). 
 
 
Prepulse inhibition of the startle reflex 
 
Prepulse inhibition, or PPI, refers to the reduction in startle response to a stimulus as a 
result of a low-intensity stimulus preceding it (Hanks & González-Maeso, 2012). It is commonly 
used as a measure of sensorimotor gating, a normal neural process in healthy humans that 
prevents overload of the senses. This attenuation of the startle response is shown to be deficient 
in patients suffering from different psychiatric illnesses; for example, it is considered an 
endophenotype of schizophrenia that models two different subsets of symptoms of the disease: 
psychosis and cognitive disruption (Braff et al., 2007). Hallucinogens are thought to disrupt 
normal sensorimotor gating behavior due to their ability to induce sensory overload and 
cognitive dysfunction; thus, psychedelics are often used as experimental tools in animals to 
model the sensory filtering deficits observed in mental illnesses such as schizophrenia (F. 
Vollenweider et al., 1998). More broadly, the use of psychedelics in animal models of PPI can 
help further our understanding of drug-induced hallucinations as a behavior in itself. 
The 5-HT2A receptor has been implicated in the mechanism of action of hallucinogen-
induced deficits in PPI in several previous studies. In humans, the 5-HT2A agonist psilocybin 
induces deficits in PPI (F. X. Vollenweider et al., 2007). Psychedelics have also been shown to 
disrupt PPI in rats. As reviewed by Halberstadt and Geyer, several drugs including DOI and LSD 
induce PPI deficits in a 5-HT2A-dependent manner. On the other hand, 5-HT2A receptor 
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activation does not consistently produce PPI deficits in mice, with some studies reporting that 
tryptamine psychedelics actually produce increases in PPI due to their action on the 5-HT1A 
receptor as well (Halberstadt & Geyer, 2016). 
 
 
Psychedelics as models of psychosis 
 
In addition to expanding our understanding of how hallucinations manifest in the brain, 
psychedelic drugs have several potential applications in medical research. Based off of their 
action through the 5-HT2A receptor as well as the involvement of this receptor in illnesses such 
as schizophrenia, psychedelics are used as models of psychosis (Halberstadt & Geyer, 2013b). 
Psychosis is defined by delusions, hallucinations, thought disorders, and catatonia (Howes & 
Murray, 2014). These models have helped us understand the role 5-HT and other 
neurotransmitter systems play in mediating this condition, leading to the development of new 
therapeutic drugs for treating the psychotic symptoms of schizophrenia. 
Schizophrenia is a complex psychiatric disorder characterized by a combination of 
behavioral and cognitive symptoms with a lifetime morbid risk of 0.7% (McGrath et al., 2008). 
The core features of schizophrenia include positive or psychotic symptoms such as delusions and 
hallucinations as described previously; negative symptoms such as impaired motivation, 
reduction in spontaneous speech, and social withdrawal; and lastly, cognitive impairment (Owen 
et al., 2016). Though the lifetime morbid risk is relatively low, its effects are severe, as life-long 
symptoms lead to disability and problems with social function. People with schizophrenia have 
an estimated two- to threefold increased risk of dying compared to the general population 
(McGrath et al., 2008) due to comorbid conditions such as cardiovascular disease, lung cancer, 
chronic obstructive pulmonary disease, and substance abuse (Olfson et al., 2015). Side effects 
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produced by second-generation antipsychotic medications, such as metabolic syndrome and 
weight gain, also contribute to this higher mortality rate (McGrath et al., 2008). Additionally, it 
is estimated that 4.9% of people will schizophrenia will commit suicide during their lifetimes 
(Palmer et al., 2005). 
As summarized by Owen et al., no specific neuroanatomical abnormalities can be 
attributed to the disorder despite the wealth of research surrounding this disease. This is 
potentially due to the fact that schizophrenia is a heterogeneous disorder comprising of a wide 
range of symptoms, and there is considerable overlap with the clinical manifestations of other 
psychiatric illnesses (2016). To address the issue of complexity, many approaches to 
understanding the pathophysiology of and improving treatment options for schizophrenia focus 
on a subset of behavioral dysfunction observed in the disorder. One area of focus is psychosis, a 
syndrome seen in many psychiatric disorders including schizophrenia as a positive symptom. 
Thus, research into the mechanisms of action of hallucinogenic drugs can prove useful for 
understanding the pathophysiology of a subset of symptoms of schizophrenia and potentially 
lead to improved treatment options for people diagnosed with this illness. 
 
 
Rationale for this study 
 
The differential effects of a mGluR2/3 antagonist in producing HTR compared to 
mGluR2 knockout mice begs the question of the role mGluR2 specifically plays in this behavior. 
It seems surprising that acute administration of antagonist of mGluR2/3 prior to DOI would 
enhance HTR, whereas in mGluR2 knockouts, arguably a full model of mGluR2 antagonism due 
to the receptor’s absence, no significant HTR is seen. I aimed to take a closer look at the role of 
mGluR2 by measuring DOI-induced HTR in wild-type and mGluR2 knockout mice using lower 
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doses of DOI than used in existing literature. By doing this, I hoped to see whether head-twitch 
behavior is truly abolished in mGluR2 knockout mice or if this genotype has experienced a 
leftward shift in its inverted U-shaped dose-response curve. If a leftward shift has occurred, 
lower doses of DOI may fall on the descending arc this curve. Additionally, I set out to induce 5-
HT2A agonist-mediated PPI deficits in male and female mice using different psychedelics and 
time intervals between the stimulus and the preceding low-intensity stimulus. While the role of 
the 5-HT2A receptor in PPI has been shown in rats and humans, the ability of mice to also show 
deficits in PPI has been uncertain. Finding a model will serve as the springboard for future 
studies using this animal model.  
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Chapter 2: Materials and Methods 
 
Animals 
 
Adult (10-20 weeks old) male C57BL/6 mice from Taconic Biosciences were used for 
the validation of the head-twitch detection system. Other head-twitch experiments involving 
mGluR2 knockout (Grm2-/-) mice were performed on adult (13-24 weeks old) males, originally 
obtained from RIKEN BioResource Center in Japan and backcrossed into the inbred 129S6/Sv 
strain for over 10 generations. Wild-type mice, denoted as Grm2+/+, from the same colony bred 
at Virginia Commonwealth University were used as controls. mGluR2 knockouts were 
previously described by Moreno et al. (2011). 
All PPI experiments utilized 129S6/Sv mice, though from several sources. Experiments 
with only wild-type males either involved adult (12-14 weeks old) mice from Taconic or adult 
(37-43 weeks old) wild-type mice, denoted as Htr2a+/+, from a 5-HT2A knockout colony 
originating in the 129S6/Sv strain and bred at Virginia Commonwealth University. Experiments 
with male and female 5-HT2A knockout (Htr2a-/-) mice were performed on adult (11-19 weeks 
old) mice with Htr2a+/+ mice used as controls. 5-HT2A knockouts were previously described by 
González-Maeso, et al. (2003). 
All mice were housed in cages with up to 5 littermates on a 12-hour light/dark cycle at 
23°C with food and water ad libitum, except during behavioral testing. Experiments were 
conducted in accordance with NIH guidelines and were approved by the Virginia 
Commonwealth University Institutional Animal Care and Use Committee (IACUC).  
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Drugs 
 
The IUPAC names and sources of drugs used are as follows: 1-(4-iodo-2,5-
dimethoxyphenyl)propan-2-amine (DOI) from Sigma Aldrich; (6aR,9R)-N,N-diethyl-7-methyl-
6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (LSD) from LIPOMED, and (R)-
(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol (volinanserin or 
M100,907) from Tocris Bioscience. Drugs were dissolved in saline and injection volumes and 
concentrations were determined based on body weight (0.01 mL/gram). All drugs were 
administered intraperitoneally (i.p.). Any indication for use of vehicle refers to an equivalent 
volume of 0.9% NaCl administered to the animal. 
 
 
Head-twitch response 
 
Surgical implantation of the head-mounted magnet was conducted as previously 
described (Halberstadt & Geyer, 2013a). Attachment of magnet-implanted ear tags was 
performed by using standard mouse ear tags affixed with a small magnet, with the south pole 
glued to the tag and the north pole facing upwards. Ear tags were attached to the lower half of 
both ears, close to the head and not obstructing the ear canal.  
Full details on data collection are described in another study (de la Fuente Revenga et al., 
manuscript submitted). Data collection for automated head-twitch detection was performed in 
non-overlapping ~500-turn enameled wire (30 AWG) coils supported in plastic cylinders (inner 
dimensions, 11 cm diameter x 14 cm tall) with both terminals of each coil connected to a phono 
preamplifier (Pyle PP444). The amplified signal output was recorded at a 1000 Hz sampling rate 
using a myDAQ (National Instruments) data acquisition system controlled through Matlab 
version R2018b (Mathworks) along with an additional NI myDAQ support package. For the 
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validation experiment, data was then processed through a high bandpass filter between 70-110 
Hz and transformed into absolute values. After double local maxima processing, each original 
wavelet is transformed into a unipolar peak that is automatically identified as a head-twitch event 
by a script when meeting certain criteria regarding frequency, duration, and intensity of the peak. 
For the dose-response experiment, data was processed through low and high bandpass filters, 
with the advanced script also including an individual event detector and a Fourier transform 
analysis detector to better exclude non-head-twitch events. 
Visual detection of head-twitch for the validation experiment was performed by 
recording mice with a video camera at close range and watching the recordings in 0.75x speed. 
This was also aided by identification of subjective, time-stamped peaks viewed through graphing 
and processing of simultaneous recorded data through a simple high bandpass filter between 70-
100 Hz. These peaks helped to ensure no potential head-twitch behavior was missed while 
viewing the videos. 
 
Western blot 
Plasma membrane preparations of mouse somatosensory cortex were performed as 
previously described for the Western blot analysis (Moreno et al., 2016). The amount of protein 
in the membrane preparations was estimated through a Bradford assay, and protein was 
denatured with heat and ß-mercaptoethanol for 5 minutes. The samples were then resolved by 
10% SDS-PAGE and transferred to a nitrocellulose membrane by electroblotting overnight. The 
membrane was blocked with blocking buffer, after which it was incubated overnight with the 
primary antibody anti-mGluR2 (Abcam; 1:1000). This antibody was shown to be specific for 
mGluR2 in a previous study (Fribourg et al., 2011). Then, the membrane was incubated with the 
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horseradish peroxidase-conjugated secondary antibody sheep anti-mouse IgG (Abcam, 1:5000), 
after which immunoreactivity was detected using the SuperSignal West Pico #34080 
chemiluminescent substrate from ThermoFisher. 
 
Prepulse inhibition of the startle reflex 
 
The SR-LAB™ Startle Response System from San Diego Instruments was used to record 
startle magnitude in response to acoustic stimuli. Mice were placed in the chambers after which a 
series of trials were presented. The magnitude of the pulse, or stimulus, was 119 dB, and of the 
prepulses were 73 dB, 77 dB, and 85 dB. The background noise was set to 69 dB. After a five-
minute acclimation period set to the background noise, the protocol utilized was as follows: 
5 stimulus-only trials 
65 trials with the following trial-types presented randomly to prevent habituation 
13 stimulus-only trials 
13 no stimulus trials 
13 73 dB prepulse and stimulus trials 
13 77 dB prepulse and stimulus trials 
13 85 dB prepulse and stimulus trials 
5 stimulus-only trials 
Each trial lasted either for a total of 200 ms, 170 ms, or 140 ms depending on the length of the 
pulse, prepulse, and the interval between the two stimuli, or interstimulus interval (ISI). One of 
the following PPI protocols was used for each experiment, with the trial length noted: 
20/80/20: 20 ms prepulse, 80 ms ISI, 20 ms pulse; each trial was 200 ms 
10/60/40: 10 ms prepulse, 60 ms ISI, 40 ms pulse; each trial was 170 ms 
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10/30/40: 10 ms prepulse, 30 ms ISI, 40 ms pulse; each trial was 140 ms 
Each session lasted about a total of 30 minutes. The 10 stimulus-only trials were excluded during 
data analysis. %PPI for each prepulse and stimulus trial was determined by averaging the peak 
startle amplitude (Vmax) for the stimulus only and the appropriate prepulse and stimulus trials and 
using the following equation: 
 %𝑃𝑃𝐼 =	 (𝑎𝑣𝑒𝑟𝑎𝑔𝑒	𝑉𝑚𝑎𝑥	𝑜𝑓	𝑠𝑡𝑖𝑚𝑢𝑙𝑢𝑠	𝑜𝑛𝑙𝑦	𝑡𝑟𝑖𝑎𝑙𝑠 − 𝑎𝑣𝑒𝑟𝑎𝑔𝑒	𝑉𝑚𝑎𝑥	𝑜𝑓	𝑝𝑟𝑒𝑝𝑢𝑙𝑠𝑒	𝑎𝑛𝑑	𝑠𝑡𝑖𝑚𝑢𝑙𝑢𝑠	𝑡𝑟𝑖𝑎𝑙𝑠)𝑎𝑣𝑒𝑟𝑎𝑔𝑒	𝑉𝑚𝑎𝑥	𝑜𝑓	𝑠𝑡𝑖𝑚𝑢𝑙𝑢𝑠	𝑜𝑛𝑙𝑦 	× 	100	
 
 
 
Statistical analysis 
Statistical analyses were performed with GraphPad Prism software version 8. Animals 
were randomly allocated into the different experimental groups. Correlation between visual 
identification vs. automated detection of HTR was assessed by linear regression. Statistical 
significance of experiments was assessed by a two-way ANOVA as each experiment had two 
independent variables. Variables assessed for the dose-response HTR experiment were treatment 
and genotype, whereas variables assessed for PPI were prepulse and treatment or genotype. Sex 
analysis involved measuring the effects of sex and prepulse. Sidak’s multiple comparisons test 
was used for post hoc analysis as it has more power, a select set of means was chosen for 
comparison, and the mean comparisons were independent of each other. The level of 
significance was chosen at p < 0.05. All data are presented as mean ± standard error of the mean 
(S.E.M).  
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Chapter 3: Results 
 
Validation of automated head-twitch response detection system 
 
Though the recently developed magnetometer-based HTR detection system addresses 
observer biases, the process of identifying events is still lengthy (Halberstadt & Geyer, 2013a). A 
newer system based on Halberstadt and Geyer’s work has been developed by de la Fuente 
Revenga et al. in which the number of sinusoidal wavelets corresponding to head-twitch events 
are detected automatically (manuscript submitted). In order to validate this new automated 
detection system, three wild-type C57BL/6 male mice with surgically implanted head magnets 
were recorded using a video camera for a total of eight 10-minute increments while head-twitch 
behavior was simultaneously automatically measured. In addition to basal head-twitch response, 
head-twitches induced with administration of DOI (0.2 mg/kg and 1 mg/kg) after the second and 
fifth increments, respectively, were also measured. There was a strong correlation observed 
between the automated and visual detection systems (r = 0.9957; slope = 0.9923) (Figure 2), with 
the automated detection system producing a false positive rate of 0% and a false negative rate of 
1.39%. 
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Figure 2: Correlation between visual and automated detection systems for measuring head-
twitch response. Each point represents one 10-minute video set and corresponding automated 
recording of a single mouse (n = 24). Mice were either given no treatment or DOI (0.2 mg/kg 
and 1 mg/kg) to generate a range of HTR counts. 
 
 
 
DOI dose-dependent head-twitch response in male 129S6/Sv wild-type (Grm2+/+) and 
mGluR2 knockout (Grm2-/-) mice 
Wild-type (Grm2+/+) and mGluR2 knockout (Grm2-/-) male mice of the 129S6/Sv strain 
were prepared for head-twitch experiments by attachment of magnet-implanted ear tags. After a 
week-long recovery process, mice were allowed to habituate to the magnetometer coils for 1.5 
hours. They were then measured a few days later for basal head-twitch response. Each mouse 
received different doses of DOI in the following order with a week-long washout period between 
each round: 2 mg/kg, 0.5 mg/kg, 0.05 mg/kg. This was followed by 0.9% saline as vehicle. Data 
were collected for 60 minutes, and analysis was completed for a 30-minute block following an 
initial 15-minute habituation period.  
0 5 10 15 20 25 30 35
0
5
10
15
20
25
30
35
Visual count based on video
A
ut
om
at
ed
 d
et
ec
tio
n 
of
 H
TR
20 
 
 
 
Figure 3: DOI dose-dependent HTR in 129S6/Sv wild-type (Grm2+/+) and mGluR2 knockout 
(Grm2-/-) mice. Head-twitch events were measured by automated detection system developed by 
de la Fuente Revenga et al. using mice (n = 4-6) with magnet-implanted bilateral ear tags. Data 
are presented as group mean ± S.E.M. Two-way ANOVA (n.s. = not significant). 
 
 
 
The vehicle was administered last to check for any residual effects of DOI following the 
final one-week washout period. The lack of difference between head-twitch counts during the 
initial basal round and final vehicle round for both groups (two-way ANOVA, F (1, 18) = 
0.02853, p = 0.8678) suggested that the washout period prescribed was sufficient, and any effects 
of DOI observed for each round were reliable. Concern for 5-HT2A receptor downregulation 
following repeated administration of DOI has also been unfounded in a previous study showing 
that rats treated every seven days for four consecutive weeks with DOI (1.25 mg/kg, i.p.) showed 
a lack of significant decrease in HTR between the first and last weeks (Gewirtz & Marek, 2000). 
Contrary to previously published data, no effect of genotype was observed for each treatment 
round (two-way ANOVA, F (1, 42) = 1.040, p = 0.3137) (Figure 3), even at the same doses of 
DOI used in other studies showing a lack of response in mGluR2 knockouts. 
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Confirmation of lack of mGluR2 expression in mGluR2 knockout (Grm2-/-) mice 
 
 I wanted to confirm whether our Grm2-/- mice truly lacked mGluR2 expression by using 
membrane preparations of mice somatosensory cortex in a Western blot analysis. The results 
showed show that these knockouts indeed did not express this receptor in comparison to Grm2+/+ 
mice (Figure 4). 
 
 
Figure 4: Western blot of mGluR2 expression in mice somatosensory cortex membrane 
preparation. Monomeric mGluR2 bands are visible for both male and female wild-type 
(Grm2+/+) mice at 100 kDa, but not mGluR2 knockout (Grm2-/-) mice. This confirms the lack of 
mGluR2 in our knockout colony. 
 
 
 
Effect of DOI on PPI in male 129S6/Sv wild-type mice 
 
In an effort to induce PPI deficits, male 129S6/Sv wild-type mice from Taconic and 
Htr2a+/+ control mice from the 5-HT2A knockout colony were treated with four different doses of 
DOI (0.5, 1, 2, and 5 mg/kg i.p.). The PPI protocol used was 20/80/20. Prepulse intensity 
produced significant differences in PPI (two-way ANOVA: F (2, 18) = 22.30, p < 0.0001). 0.5 
mg/kg DOI had an effect on PPI in Htr2a+/+ control mice (two-way ANOVA: F (1, 24) = 8.691, 
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p = 0.0070; post hoc: (73 dB prepulse; vehicle vs. DOI) p = 0.0060). Also, 1 mg/kg DOI had an 
effect on PPI in wild-type mice from Taconic (two-way ANOVA: F (1, 18) = 6.860, p = 0.0174; 
post hoc: (73 dB; vehicle vs. DOI), p = 0.0036) with a significant prepulse x treatment 
interaction (p = 0.0281). However, surprisingly these two doses of DOI improved PPI in wild-
type and Htr2a+/+ control mice instead of producing deficits. Using 2 mg/kg and 5 mg/kg of DOI 
did not result in the same improvement in PPI, though a slight trend was still observed (Figure 
5). 
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Figure 5: Dose-dependent effects of DOI on PPI in male 129S6/Sv wild-type mice. A Htr2a+/+ 
from 5-HT2A knockout colony, B-D Taconic. PPI results are shown in mice administered vehicle 
or DOI (0.5 mg/kg) immediately prior to testing (A), DOI (1 mg/kg) 15 minutes prior to testing 
(B), DOI (2 mg/kg) 15 minutes prior to testing (C), and DOI (5 mg/kg) immediately prior to 
testing (D). n = 5 for each group in A, and n = 4 for each group in B, C, and D. Data are 
presented as group mean ± S.E.M. Two-way ANOVA with Sidak’s multiple comparisons test (* 
p < 0.05, ** p < 0.01). 
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Effect of LSD on PPI in male 129S6/Sv wild-type mice  
 
In order to determine whether DOI’s improvement of PPI was a behavior specific to the 
drug or was a result of psychedelic action at the 5-HT2A receptor, I repeated the experiment using 
LSD (0.24 mg/kg) in male 129S6/Sv wild-type mice from Taconic. The same protocol as above, 
20/80/20, was used. LSD also showed an enhancing effect on PPI (two-way ANOVA: F (1, 18) 
= 9.000, p = 0.0077; post hoc: (73 dB prepulse; vehicle vs. LSD), p = 0.0489) (Figure 6). 
 
 
Figure 6: Effect of LSD on PPI in male 129S6/Sv wild-type mice. Mice were from Taconic. PPI 
results are shown in mice administered vehicle (n = 4) or DOI (0.5 mg/kg) (n = 4) immediately 
prior to testing. Data are presented as group mean ± S.E.M. Two-way ANOVA with Sidak’s 
multiple comparisons test (* p < 0.05, ** p < 0.01). 
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Effect of M100,907 on DOI-induced PPI improvement in male 129S6/Sv wild-type mice 
 
I hypothesized that the lack of 5-HT2A agonist-induced PPI deficits in the previous two 
experiments may be due to the durations of the prepulse, ISI, and pulse used. Aubert et al. 
showed that slight differences in intensities and durations of acoustic stimulus could affect PPI 
results (2006). In a strain comparison study, peak PPI was reached with prepulses 5 and 10 dB 
above baseline at a duration of 15 ms, and at a duration of 10 ms for a prepulse 15 dB above 
baseline in 129S2 mice. Additionally, a 10 ms long prepulse produced peak PPI with ISIs of 100, 
50, and 50 ms at intensities of 5, 10, and 15 dB above baseline, respectively, while utilizing a 40 
ms pulse (Aubert et al., 2006). As our PPI protocol utilizes prepulses 4, 8, and 16 dB above 
baseline, and mice with a 129S6/Sv background, I felt that I was able to make a relatively fair 
comparison and used the data from this paper to adjust our protocol accordingly, lowering our 
prepulse duration and ISI. I chose a 10 ms prepulse, 60 ms ISI, and 40 ms pulse (10/60/40) to use 
moving forward. This decision was supported by the observation that in another study using CD-
1 mice, PPI deficits were successfully induced by DOI (0.5 mg/kg, i.p.) using the same pulse and 
interval durations (Ibarra-Lecue et al., 2018). 
Mice were randomly assigned to receive a pretreatment of 0.9% saline or M100,907 (1 
mg/kg) and a treatment of 0.9% saline or DOI (0.5 mg/kg). Despite the adjustments in protocol, I 
continued to observe improvements in PPI as a result of DOI administration in 129S6/Sv male 
wild-type mice (two-way ANOVA: F (1, 54) = 11.31, p = 0.0014; post hoc: (73 dB; saline and 
saline vs. saline and DOI), p = 0.0003), with a significant prepulse x treatment interaction (two-
way ANOVA: F (2, 54) = 5.195, p = 0.0086). Here, I was also able to show that DOI’s effects 
are mediated through the 5-HT2A receptor as I observed a significant effect of the 5-HT2A 
antagonist M100,907 on PPI in DOI-treated animals (two-way ANOVA: F (1, 51) = 10.43, p = 
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0.0022; post hoc analysis (saline and DOI vs. M100,907 and DOI at 73 dB), p = 0.0001) with 
significant prepulse x treatment interaction (two-way ANOVA: F (2, 51) = 5.961, P=0.0047). By 
pharmacologically blocking the 5-HT2A receptor with M100,907, DOI’s improvement in PPI was 
absent compared to DOI only-treated group. M100,907 alone had no effect on PPI in comparison 
to the saline only-treated group (Figure 7). 
 
Figure 7: Effect of M100,907 on DOI-induced PPI improvement in male 129S6/Sv wild-type 
mice. Mice were from Taconic. PPI results are shown in mice administered saline and saline, 
saline and DOI (0.5 mg/kg), M100,907 (1 mg/kg) and saline, and M100,907 (1 mg/kg) and DOI 
(0.5 mg/kg). Time between pretreatment and treatment was 15 minutes. n = 9-10 for each group. 
Data are presented as group mean ± S.E.M. Two-way ANOVA with Sidak’s multiple 
comparisons test (** p < 0.01, *** p < 0.001). 
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Effect of DOI on PPI in male and female 129S6/Sv wild-type (Htr2a+/+) and 5-HT2A 
knockout (Htr2a-/-) mice 
To further confirm the dependency of DOI on the 5-HT2A receptor for facilitating 
improvements in PPI, I used a cohort of male and female 129S6/Sv wild-type (Htr2a+/+) and 5-
HT2A knockout (Htr2a-/-) mice with the 10/60/40 PPI protocol. Interestingly, I was unable to 
replicate the DOI-induced enhancement of PPI in male Htr2a+/+(Figure 8) despite using the same 
protocol and dose of DOI as in Figure 7 and the same dose of DOI and mice as in Figure 5A. No 
variation based on treatment was observed in Htr2a-/- male mice. On the other hand, female 
Htr2a+/+mice did display an effect of DOI on PPI (two-way ANOVA: F (1, 63) = 12.69, p = 
0.0007; post hoc: (73 dB prepulse; saline vs. DOI) p = 0.0086, (77 dB prepulse; saline vs. DOI) p 
= 0.0305) (Figure 8). Similar to males, no effect of treatment was seen in Htr2a-/- mice. 
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Figure 8: Effect of DOI on PPI in male and female 129S6/Sv wild-type (Htr2a+/+) and 5-HT2A 
knockout (Htr2a-/-) mice. PPI results are shown in mice administered saline or DOI (0.5 mg/kg). 
n = 8-9 for each group of males and n = 7-12 for each group of females. Data are presented as 
group mean ± S.E.M. Two-way ANOVA with Sidak’s multiple comparisons test (* p < 0.05, ** 
p < 0.01, *** p < 0.001). 
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Effect of genotype and sex on PPI in male and female 129S6/Sv wild-type (Htr2a+/+) and 5-
HT2A knockout (Htr2a-/-) mice 
There was no effect of genotype on PPI found in either male or female mice (Figure 9) 
when comparing the saline groups from Figure 8. Additionally, there was no effect of sex 
observed on baseline PPI. 
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Figure 9: Effect of genotype and sex on PPI in male and female 129S6/Sv wild-type (Htr2a+/+) 
and 5-HT2A knockout (Htr2a-/-) mice. PPI results are separated by prepulse intensity. n = 8-9 for 
each group of males and n = 7-12 for each group of females. Data are presented as group mean ± 
S.E.M. 
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Effect of shorter ISI on DOI’s effect on PPI in male and female 129S6/Sv wild-type 
(Htr2a+/+) and 5-HT2A knockout (Htr2a-/-) mice 
 
I then hypothesized that shortening the ISI would produce DOI-induced PPI deficits in 
males and females. A study in healthy human volunteers described that psilocybin, a 5-HT2A 
receptor agonist, produced vastly different effects on PPI depending on the ISI used. While 
psilocybin had no effect on PPI with a 60 ms ISI, it increased PPI at ISIs above 120 ms and 
reduced PPI at an ISI of 30 ms (F. X. Vollenweider et al., 2007). Based off of these findings, I 
decided to repeated our experiments in male and female wild-type (Htr2a+/+) and 5-HT2A 
knockout (Htr2a-/-) mice after reducing our ISI to 30 ms; the protocol used was 10/30/40. 
However, even with a shorter ISI, DOI did not produce an effect on PPI in male Htr2a+/+ 
mice. Additionally, DOI did not have an effect on Htr2a-/-. However, female Htr2a+/+ mice 
continued to display improved PPI in response to DOI (two-way ANOVA: F (1, 60) = 5.471, p = 
0.0227) (Figure 10). This effect was again shown to be dependent on the 5-HT2A receptor as it 
was absent in Htr2a-/- mice.  
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Figure 10: Effect of shorter ISI on DOI’s effects on PPI in male and female 129S6/Sv wild-type 
(Htr2a+/+) and 5-HT2A knockout (Htr2a-/-) mice. PPI results are shown in mice administered 
saline or DOI (0.5 mg/kg). n = 7 for each group of males and n = 7-11 for each group of females. 
Data are presented as group mean ± S.E.M. Two-way ANOVA (* p < 0.05). 
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Effect of genotype and sex on DOI’s effect on PPI in male and female 129S6/Sv wild-type 
(Htr2a+/+) and 5-HT2A knockout (Htr2a-/-) mice using a shorter ISI 
No effect of genotype was observed on baseline PPI with the shorter ISI in both males 
and females (Figure 11) when comparing the saline groups from Figure 10. Additionally, there 
was no effect of sex on baseline PPI as well. 
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Figure 11: Effect of genotype and sex on DOI’s effect on PPI in male and female 129S6/Sv 
wild-type (Htr2a+/+) and 5-HT2A knockout (Htr2a-/-) mice using a shorter ISI. PPI results are 
separated by prepulse intensity. n = 7 for each group of males and n = 7-11 for each group of 
females. Data are presented as group mean ± S.E.M.  
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Chapter 4: Discussion 
 
In contrast to previously published literature suggesting the mGluR2 is necessary for 
DOI-induced HTR, Grm2-/- mice still responded to the DOI and exhibited HTR at multiple low 
doses, despite using mice from the same mutant colony as reported by others (Moreno et al., 
2011). Additionally, two doses of DOI, 0.5 mg/kg and 1 mg/kg, produced unexpected 
improvements in PPI in male 126S6/Sv wild-type controls (Htr2a+/+) and 129S6/Sv wild-type 
mice from Taconic, respectively, using the 20/80/20 protocol. The same effect was observed 
using another psychedelic, LSD (0.24 mg/kg), in male 129S6/Sv wild-type mice from Taconic 
also using the 20/80/20 protocol. Using a 10/60/40 protocol, the DOI (0.5 mg/kg) enhancing 
effect was replicated in 129S6/Sv wild-type mice from Taconic; thus, I continued my 
experiments using this protocol as a baseline. DOI’s effect was absent following pretreatment 
with the 5-HT2A antagonist M100,907 (1 mg/kg), suggesting this improvement is 5-HT2A-
dependent. Surprisingly, when using this adjusted 10/60/40 protocol in male 129S6/Sv Htr2a+/+ 
mice, DOI produced no effect. DOI-induced improvements in PPI were still present in female 
129S6/Sv Htr2a+/+ mice, and this effect was absent in Htr2a-/- mice, again suggesting the 5-HT2A 
receptor mediates this increase in PPI. DOI also produced PPI increases in female 129S6/Sv 
Htr2a+/+ mice using a shorter ISI with the 10/30/40 protocol, but again, no response was seen in 
males.  
The HTR results could be explained by the differences in genetic background of the mice 
used. Our mGluR2 knockout colony originated in a C57BL/6 background and was backcrossed 
into the 129S6/Sv strain. The difference in genetic makeup between the colony’s current 
generation and the generation used in our lab’s previous publications could account for the 
differences in head-twitch results. A closer look at the data published by Moreno et al. shows 
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that the Grm2-/- mice used had been backcrossed for at least 10 generations, meaning that no 
more than 0.09% of the mouse genetic makeup was of the C57BL/6 strain (2011). Though this is 
small, currently these mice contain even less of a C57BL/6 background as breeding has been 
ongoing for several years since. Additionally, there could be compensatory mechanisms at play 
after generations of mGluR2 knockout mice breeding, where another receptor could be 
overexpressed to support the functions of the missing mGluR2. Further studies should analyze 
mRNA levels of different GPCRs in these knockout mice to assess whether there is an 
overcompensation compared to wild-types. Both Grm2+/+ and Grm2-/- should also be compared 
to wild-type 129S6/Sv mice from Taconic, as an inbred substrain could have been developed as 
well if mouse breeding was not carried out appropriately. Overall, while these results are 
surprising, it’s important to remember that DOI’s primary target, the 5-HT2A receptor, was still 
present in these mice. 
While PPI is a cross-species measure of sensorimotor gating, there have been reported 
differences in the neural mechanisms of PPI between rats and mice (Geyer et al., 2002; van den 
Buuse, 2010).  For instance, 5-HT1A receptor agonists have been shown to disrupt PPI in rats, but 
display the opposite effect in mice (Geyer et al., 2001; Gogos et al., 2008). However, DOI is not 
known to act at the 5-HT1A receptor, so our results cannot be explained by this reasoning (Canal 
& Morgan, 2012). I also showed that blocking the 5-HT2A receptor pharmacologically in males 
and using female receptor gene knockout models resulted in the absence of DOI’s increase in 
PPI, suggesting this is a 5-HT2A-specific behavior. 
Since it is understood that different strains of mice have varying baseline PPI levels and 
responses to drugs (van den Buuse, 2010), I used 129S6/Sv mice for all experiments. However, 
there are other sources of potential differences between the mice from the 5-HT2A knockout 
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colony and newly acquired mice from Taconic. Though our 5-HT2A knockout colony originated 
in the 129S6/Sv strain from Taconic, it has been maintained at a different facility for years. 
Environmental differences between Taconic and Virginia Commonwealth University’s facilities 
could have led to epigenetic changes causing genetic drift in our 5-HT2A knockout colony. This 
could explain the discrepancy between Figures 7 and 8A, in which the same dose of DOI and the 
same PPI protocol (10/60/40) resulted in different findings. This theory is supported by a recent 
analysis that assessed mice of the same substrain obtained from three different suppliers in a 
multitude of behavioral tests; the study found that the origin of the mice had an effect on test 
results (Åhlgren & Voikar, 2019). 
Additionally, a review by van de Buuse emphasized how different interstimulus intervals 
could produce alternate results in PPI experiments (van den Buuse, 2010). This could explain the 
discrepancy between our results in Figures 5A, 8A, and 10A, in which the same dose of DOI was 
administered and the same mice (Htr2a+/+) were used, but three different PPI protocols were 
tested. For this same reason, future studies should incorporate a longer ISI to test whether this 
protocol change results in altered PPI findings. If multiple PPI protocols continue to produce 
improvements in PPI, these results could support the use of psychedelics as therapeutic drugs. 
Lastly, the sex differences observed in response to DOI-induced changes in PPI follows 
previous work on sex differences in behavioral tests, including PPI, using LSD; however, this 
study uses rats and shows that males and females in one phase of the oestrus cycle produce PPI 
deficits with LSD in comparison to females in a different phase (Pálenícek et al., 2010). Still, it 
is interesting to know our results are not in isolation. Future studies should also continue to 
incorporate data from both male and female mice to help identify the mechanisms underlying 
these differences in hallucinogenic behavior. 
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This study reveals the important effect that mice genetic and environmental background 
can have on the results of behavioral experiments. It also touches on the difficulties in 
reproducing results across different labs as well as translating behavioral results across species, 
suggesting that the generalizability of results from scientific research is limited. Lastly, it brings 
to light the potential for sex differences in hallucinogenic drug action.  
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